GRAIL, Inc. Faces Securities Fraud Lawsuit Over NHS-Galleri Trial Misrepresentations
A securities fraud class action lawsuit has been filed against GRAIL, Inc. (NASDAQ:GRAL), alleging that the company and senior executives misled investors regarding its NHS-Galleri cancer screening trial's design, progress, and efficacy between May 13, 2025, and February 19, 2026. The lawsuit claims GRAIL selectively promoted favorable results while concealing limitations in its three-year follow-up timeline to achieve the primary endpoint of reducing late-stage cancers. On February 19, 2026, GRAIL announced that it failed to meet this key trial objective and admitted a flawed timeline assumption. This revelation triggered an immediate market reaction: GRAL shares dropped by over 50% in one day, wiping out more than $2.2 billion from the company's market capitalization. Hagens Berman Sobol Shapiro LLP is representing affected investors who may qualify to lead or participate in a class action lawsuit before August 4, 2026.
Tickers: $GRAL
Topics: class action clinical trial results GRAIL, Inc. NASDAQ:GRAL stock crash